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A B S T R A C T
Background: Advanced dementia is a prevalent health problem in geriatric patients. These patients
usually suffer from several chronic diseases, frequently leading to an end-of-life situation lasting months
or years, generating complex and often inappropriate medication regimens.
Objectives: Describe the re-orientation of drug therapy in patients with advanced dementia utilizing a
systematic medication review process.
Methods: This non-experimental pre-post analysis included all patients with advanced dementia
admitted to acute geriatric unit (AGU) over one year. Medications were reviewed by a multidisciplinary
team and together with the patient caregivers; new therapeutic objectives based on end-of-life care
principles were established. Medications were classiﬁed as preventive, therapeutic, or symptomatic. The
average number of medications per patient pre- and post-admission was compared.
Results: We included 73 patients (mean age 86.1 years, mean Barthel Index: 14.5/100). At admission,
patients had a mean of 7.27 drugs compared to 4.82 at discharge (66.85% reduction, P < 0.05). The main
drugs withdrawn were cardiovascular and hematological (35.76%). Drugs for prevention decreased by
66.85% (from 1.8 to 0.6, P < 0.05) and those for symptomatic care decreased by 17,52% (from 2.34 to 1.93,
P < 0.05).
Conclusion: Medication therapy plans in patients with advanced dementia often do not meet their
therapeutic goals. The proposed methodology is a useful tool to assess therapeutic appropriateness.
 2013 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved.
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As the world population continues aging, there will be an
increasing number of patients with advanced, complex chronic
disease [1]. Many of these patients will deteriorate clinically,
functionally, or cognitively, ultimately resulting in a situation of
limited prognosis [2]. Advanced dementia is one such chronic
condition, and is a problem of serious consequence with a
prevalence as high as 80% in nursing home patients, making it a
pressing concern for both patients and providers [3,4].
Multi-morbidity is common amongst patients with chronic
conditions. This often leads to complex treatment regimens,* Corresponding author. Acute Geriatric Units, Hospital General de Vic. C/
Francesc Pla el Vigata`, s/n, 08500 Vic, Barcelona, Spain. Tel.: +34 93 889 1111, ext:
1503.
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http://dx.doi.org/10.1016/j.eurger.2013.10.011evidenced by the presence of polypharmacy (deﬁned as ﬁve or
more medications) [5] and by the heterogeneity of therapeutic
goals, which often include preventive, therapeutic, and sympto-
matic objectives. When approaching end-of-life care, as in the case
of advanced dementia, both the number of and the indication for
the medication should be evaluated, with the priority placed on
symptomatic versus prevention care.
Pharmaceutical care is well deﬁned in the last days or hours of
life, with the primary focus on symptomatic care and the
alleviation of suffering [6–8]. In contrast, pharmacological care
during the broader end-of-life time frame is less well deﬁned and
there are no speciﬁc guidelines, owing in part to limited clinical
trial data in this population and the uncertain prognosis of these
patients [6,9]. Although during this stage a primary goal is
symptom management, this is not incompatible with other
treatment objectives. Thus, a dynamic and systematic review of
a patient’s medication proﬁle is called for, with the objective ofiatric Medicine Society. All rights reserved.
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requires a re-orientation in regard to therapies for chronic
conditions, including both initiating discontinuing, medications
chronic medications.
Raising the withdrawal of chronic therapies constitutes a
professional challenge for several reasons:
 it requires the identiﬁcation of patients who are within the last
months or year of life;
 it requires deﬁning new drug therapy goals, evaluating the
potential risks of discontinuing a speciﬁc medication [10].
Both of these are feasible in patients with advanced dementia, a
disease well established as a terminal illness where the primary
goals focus on symptomatic care [11]. Furthermore, removal of
unnecessary drugs may be beneﬁcial to the patient, as complex
drug therapy and the resulting polypharmacy may increase the risk
of adverse drug events [12–14].
Recently, published recommendations for end-of-life pharma-
cotherapy provide guidance on individualizing drug therapy
regimens [15–17]. This requires re-thinking the prescription
process, utilizing criteria speciﬁc to this patient population
including:
 avoiding drug therapy where the primary goal is extending life;
 avoiding treatments for primary prevention (the time-to-beneﬁt
is longer than the patient’s life expectancy);
 individualizing the use of secondary prevention (ensuring time-
to-beneﬁt is within the expected life span);
 reducing the number of medications per patient, moving from a
state of polypharmacy to oligopharmacy (less than 5 medications
per patient);
 deﬁning treatment goals jointly with patients or caregiver;
 acknowledging that the process will be dynamic and will require
continuous reassessment;
 involving multiple health care professionals to create multi-
disciplinary care teams [15].
The objective of the study is to describe the re-orientation of
drug therapy utilizing a systematic approach focusing on patient
cantered goals in a group of patients with advanced dementia
admitted to an acute geriatric unit (AGU).
2. Methods
We conducted a non-experimental pre-post evaluation of the
standard medical management of patients admitted to the AGU in
a secondary care regional hospital in Catalonia, Spain between May
2011 and April 2012. This evaluation includes patients with
advanced dementia, deﬁned as either having all three of the
following: an inability to complete activities of daily living (Barthel
index less than or equal to 30/100), incontinence and difﬁculty
recognizing family members (Global Deterioration Scale greater
than or equal to 6d in case of Alzheimer type dementia). Patients
who died during hospitalization were excluded.
2.1. Developing medication therapy plan
In order to create a new patient cantered drug therapy regimen,
all patient medication proﬁles were systematically evaluated in a
three-stage process by a multidisciplinary team consisting of two
geriatricians and a clinical pharmacist (Fig. 1).
2.1.1. Patient centered assessment
We conducted an initial multidimensional geriatric assessment
of clinical, functional, cognitive, and social indicators. The objectiveof this review was to employ a goal-oriented approach, taking into
account the evolutionary state of the chronic disease, to guide care
decisions [18]. If patients were not able to communicate for
themselves, the values and preferences of caregivers were taken
into account when establishing therapeutic goals. At the end of this
review, new therapeutic goals were established, guided by the
known criteria for recognizing key transitions at the end-of-life
[19].
2.1.2. Diagnosis centred assessment
Patient health problems were listed together with the medica-
tions prescribed for each diagnosis. Each medication was then
classiﬁed by its objective and placed into one of the following
categories:
 preventive therapies (primary or secondary);
 therapeutic or curative treatments;
 or symptomatic therapy.
In this stage, we evaluated the applicability of clinical practice
guidelines according to each patient’s therapeutic goals. Although
all medications were reviewed, special attention was paid to those
previously identiﬁed in the literature as having a high potential for
discontinuation at the end-of-life, such as those used for primary
prevention. (Table 1) [15–17]. This allowed us to make prescribing
decisions based on both the therapeutic objective of the
medication and the previously established therapeutic goals of
the patient.
2.1.3. Medication centred assessment
We also assessed the medication proﬁle for drug-related
problems (Fig. 1).
Based on this process, we developed patient-speciﬁc thera-
peutic plans for each patient.
2.2. Data collection and analysis
Basic patient demographic information was collected, including
age, sex, living arrangements (own home or residence), and
discharge destination. The Barthel Index was used to measure
functionality at admission and at discharge. The chief complaint,
length of stay, and presence of delirium during hospitalization
were also recorded. To assess the presence of polypharmacy, the
number of medications pre- and post-admission were collected,
along with the number of medication added or discontinued
during the hospitalization.
Finally, we performed a statistical analysis consisting of
calculating the differences in the number of medications at
admission and discharge using the non-parametric Wilcoxon
signed-rank test (SPSS software 15.0) with a signiﬁcance of
P < 0.05. Non-normality of distribution was assessed by goodness-
of-ﬁt test of Kolmogorov–Smirnov.
3. Results
3.1. Patient demographics
During the study year, a total of 934 patients were admitted to
the AGU, of which 73 (7.81%) met the inclusion criteria.
Of those included in the study, 79.45% were women and the
mean age was 86.1 years (SD: 5.73, range 72–100). The majority of
patients (58.9%) were institutionalized (from nursing homes) and
the remainder were living at home. The mean Barthel Index of the
study population was 14.5/100.
The main admission diagnoses were: trauma 35.61% (fracture of
the femur 84.52%), infection 36.98% (respiratory infections 44.34%
Fig. 1. Methodology for development of patient centered medication plan.
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20.54% (worsening of heart failure, acute coronary syndrome and
cardiac dysrhythmia, etc.). The average stay was 4.89 days (global
average during the same period for the entire unit was 6.2 days).
Almost half (43.80)% of the patients had acute delirium during
hospitalization. At discharge, 57.5% of the patients were referred to
their original place of residence and the remaining 42.5% were
discharged to an intermediate care hospital.
3.2. Medication proﬁles
Patients had an average of 7.27 medications prior to hospita-
lization, and 82.2% met the criteria for polypharmacy. Of these
medications, 24.80% (average of 1.81 per patient) were for
prevention, of which 76.2% were for primary prevention (average
of 1.38 per patient) and 23.8% were for secondary prevention
(average of 0.43 per patient). Medications for therapeutic purposes
represented 42.91% of all medications (mean of 3.12 per patient),
and those for symptomatic care represented 32.2% (mean of 2.34
per patient) (Table 2).The average number of medications per person at discharge
decreased by 2.45 per person (66.30%) to 4.8, excluding temporary
medications initiated to address the chief complaint (Table 2).
Decreases were seen in all groups (preventive, therapeutic and
symptomatic) although the most commonly discontinued medica-
tions were for prevention. Two-thirds (66.85%) of the preventive
medicines were discontinued due to lack of evidence in an elderly
patient population, with the vast majority (78.50%) indicated for
primary prevention. More than a quarter (27.24%) of drugs
designated for treatment were discontinued due to lack of a clear
indication, and drugs for symptomatic control were also decreased
by 17.52%.
The most common systems affected by medication disconti-
nuations were the cardiovascular and blood system, accounting for
35.70% of all discontinued medications, followed by drugs for the
nervous system (19.56%), drugs related to the metabolism or
nutrition (16.77%), and musculoskeletal system (14.52%) (Table 3).
During the admission, new medications were started, of which
54.30% were to treat the chief complaint and were of limited
duration. The most frequently added new medications were:
Table 1
Therapeutic groups, based on anatomical therapeutic chemical (ATC) classiﬁcation system, evaluated in patients at the end-of-life.
Anatomical group Therapeutic class
A: Alimentary tract and metabolism
Antidiabetics Metformin
Thiazolidinediones
Anti-ulcer (Gastroprotectants) Proton Pump Inhibitors
Antihistamines
B: Blood and blood forming organs
Antiplatelet and anticoagulant Acetylsalicylic acid and clopidogrel
Anti-anemics Acenocoumarol, warfarina, dabigatran, rivaroxaban
Iron
Vitamin B12; folic acid
Lipid modifying agents Statins
Fibrates
C: Cardiovascular
Antihypertensives Angiotensin converting enzyme inhibitors for prevention of nephropathy
Angiotensin II receptor antagonists for prevention of nephropathy
H: Hormonal
Drugs for bone-disease Calcium and vitamin D supplements
Bisphonophonates
Teriparatide
Estrogen
J: Anti-infectives
Bacterial infections Prophylactic antibiotics Antibio´ticos proﬁla´cticos
L: Antineoplastics and immunomodulating agents
Cytotoxics Cytotoxic and chemotherapeutic agents
Vaccines Preventive vaccines
M: Musculoskeletal
Anti-inﬂammatory Non-steroidal anti-inﬂamatories
Antiarthritics Cytotoxic and biologic therapy (monoclonal antibodies)
N: Nervous system
Anti-dementia drugs Acetylcholinesterase inhibitors
Memantine
Anti-Parkinson Anticholinergics to treat extrapyramidal effects of neuroleptics
Antidepressants Tricyclic antidepressants
Anxiolytics and hypnotics Benzodiazapines with long half-life
R: Respiratory system
Antiasthmatics Theophyline
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corticosteroids (8.60%) and gastroprotectants (6.99%). Although
all patients were receiving end-of-life care, some medications were
also added for therapeutic purposes, representing 20.43% of all
new medications. Digoxin for atrial ﬁbrillation and antihyperten-
sives were the most commonly added. Finally, 24.73% of new drugs
were to improve symptom control, such as analgesics NSAIDs
(26.90%), laxatives (18.40%) and neuroleptics (16.10%).
Although the total number of medications in each three groups
decreased, because signiﬁcantly more medications for prevention
were discontinued compared to therapeutic or symptomatic care,
the later two represented a larger proportion of the overall
medication proﬁle at discharge (Table 2). For example, at
admission, therapeutic medications represented 42.90% of all
drugs, but this proportion rose to 47.10% at discharge. Similarly,
symptomatic medications went from 32.20% to 40.20% while
preventive medications fell from 24.80% to only 12.65%.Table 2
Preventive, therapeutic and symptomatic medications affected by proposed changes in
Average number of medications per patient
Admission Discharge (including short-term
and long-term medications)
Preventive therapies 1.81 (24.8%) 1.44 (19.61%) 
Primary 1.38 (18.9%) 1.30 (17.71%) 
Secondary 0.43 (5.9%) 0.14 (1.90%) 
Therapeutic treatments 3.12 (42.91%) 3.41 (46.45%) 
Symptomatic treatment 2.34 (32.2%) 2.49 (33.92%) 
Total 7.27 7.34 4. Discussion
The optimization of medication therapy in frail patients at the
end-of-life remains a challenge to the current healthcare system.
This study demonstrates that patients with advanced dementia
are often maintained on drug therapy for chronic conditions that
fail to take into account the patient’s global condition. This is
reﬂected quantitatively by the fact that polypharmacy is
common amongst this population and qualitatively, in that
the therapy was not targeted to the real needs of the patient. We
propose a systematic methodology that personalizes medication
therapy, which we applied to patients with advanced dementia.
In this subgroup of patients, we signiﬁcantly decreased the
number of prescribed medications, from an average of 7.3
chronic medications per patient at admission to 4.8 at discharge.
This reduction was primarily seen amongst medications for
primary prevention. therapeutic goals.
Discharge (excluding short-term,
admission-related medications)
Difference between
admission and discharge
P
0.60 (12.65%) –1.21 (–66.85%) < 0.05
0.43 (8.92%) –0.95 (–68.84%) < 0.05
0.17 (3.52%) –0.26 (–60.46%) < 0.05
2.27 (47.1%) –0.85 (–27.24%) < 0.05
1.93 (40.24%) –0.41 (–17.52%) < 0.05
4.8 –2.45 (–66.3%) < 0.05
Table 3
Type of medications changed or discontinued by organ system and drug class.
Organ system Drug class
Cardiovascular and
hematologic (35.76%)
Antiplatlets: 13.41%
Antihypertensives: 9.50%
Hipolypidemics: 5.59%
Anticoagulants: 2.23%
Other cardiovascular: 5.03%
Nervous system (19.56%) Antidepressants: 9.50%
Benzodiazapines and neuroleptics: 8.38%
Dementia therapies: 1.68%
Alimentary tract and
metabolism (16.77%)
Nutritional supplements: 8.94%
Gastroprotectants: 6.15%
Antidiabetics: 1.68%
Musculoskeletal (14.52%) Antiresorptive: 7.82%
Analgesics (NSAIDs): 6.70%
Respiratory (1.68%) Anti-asthmatics
Genitourinary (0.56%) Antispasmodics and anticholinergics
Other (11.15%) Eyedrops
Low value intrinsic medications: brain
vasodilators and nootropics drugs;
chondroprotectors
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patients in other healthcare settings [20–22]. A program to address
polypharmacy in elderly community dwelling patients resulted in
an average decrease of 4.4 medication per patient [21] whereas an
intervention in a geriatric specialty hospital decreased medications
by 47% (2.8) per patient [20]. Importantly, these previously
published studies did not report an increase in adverse events, and
families reported an increase in the quality of life, functionality,
and cognitive status.
Although it was not the primary objective of this study, our
results conﬁrm that patients with advanced dementia present with
high levels of dependency, as more than half of the patients in this
study were living in an institutional setting. We also conﬁrm that
in this population, infection and trauma are the most frequent
reasons for hospitalization, followed by the worsening of other
chronic conditions. Furthermore, we observed frequent transitions
between care levels with nearly half of discharged patients not
returning to the original living situation and with many of these
going to an intermediate care unit. This highlights the need for
clear communication between hospitalists, primary care providers,
patients, and healthcare providers in intermediate care facilities to
prevent medication errors and ensure continuity of care [23].
Studies in patients with advanced dementia have typically
emphasized the natural history of the disease and the resulting
problems, but few have resulted in interventions that improve
pharmacological outcomes [10]. Particularly in the area of drug
therapy, interventions have primarily focused on anticholines-
terases and neuroleptics [24], but interventions addressing the
overall patient status are lacking. In this study, we describe a
methodology to personalize medication therapy in patients with
advanced dementia, resulting in medication therapy plans that
take into account the global status of the patient. This type of
patient-centred drug therapy intervention is the basis of patient-
centred care [18], and is applicable to other patients at the end-of-
life, including those with extremely frailty or with advanced stage
organ disease or cancer [25]. For example, our proposed systematic
review of drug therapy can be used in parallel with existing tools
designed to identify potentially inappropriate medications in the
elderly, such the Beers criteria or STOPP/START [26,27], which may
not always take into account the needs of an individual patient.
This work reﬂects the process developed by our multidisci-
plinary team of geriatricians and a clinical pharmacist, and
represents a continuous evaluation of the drug therapy proﬁle.The basis of this process is establishing appropriate therapeutic
goals at the end-of-life, and then realigning drug therapy to meet
these goals.
One of the limitations of the current study is the lack of data on
patient outcomes. Assessing the health and quality of life, adverse
events due to medication withdrawal, and the economic impact of
our intervention would have strengthened the results. Future
research should address these questions.
In conclusion, patients with advanced dementia often receive
inadequate drug therapy with many medications prescribed for
primary prevention, and the majority of patients meeting the
criteria for polypharmacy. Consequently, these patients could
beneﬁt from the personalization of their medication therapy from
a multidisciplinary team, leading to better agreement between
clinical objective that prioritize symptomatic control and the
patient’s medication proﬁle.
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